Crizotinib CAS 877399-52-5 Agbeyewo ≥99.0% API Didara Giga Factory
Shanghai Ruifu Chemical Co., Ltd jẹ olupilẹṣẹ asiwaju ti Crizotinib (CAS: 877399-52-5) pẹlu didara to gaju.Kemikali Ruifu le pese ifijiṣẹ agbaye, idiyele ifigagbaga, iṣẹ ti o dara julọ, kekere ati awọn iwọn olopobobo ti o wa.Ra Crizotinib,Please contact: alvin@ruifuchem.com
| Orukọ Kemikali | Crizotinib |
| Awọn itumọ ọrọ sisọ | Xalkori;PF-02341066;Crozotinib;Crizotinib Xalkori;3- [1- (2,6-Dichloro-3-Fluoro-phenyl) -ethoxy] -5- (1-Piperidin-4-yl-1H-pyrazol-4-yl) -pyridin-2-ylamine;(R) -3- [1- (2,6-Dichloro-3-Fluorophenyl) ethoxy] -5- (1-Piperidin-4-yl-1H- pyrazol-4-yl) pyridin-2-ylamine |
| Nọmba CAS | 877399-52-5 |
| Iṣura Ipo | Ninu Iṣura, Iwọn iṣelọpọ Ti o to Awọn ọgọọgọrun Kilogram |
| Fọọmu Molecular | C21H22Cl2FN5O |
| Òṣuwọn Molikula | 450.34 |
| Ojuami Iyo | 192℃ |
| iwuwo | 1,47 ± 0,10 g / cm3 |
| Ibi ipamọ otutu | Iwọn otutu yara |
| Ipilẹṣẹ | Shanghai, China |
| Brand | Ruifu Kemikali |
| Nkan | Awọn pato |
| Ifarahan | Funfun to Pa-White Powder |
| Idanimọ | Nipasẹ IR, HPLC |
| wípé Solusan | Ni ibamu si Standard |
| Pipadanu lori Gbigbe | ≤1.00% |
| Aloku lori Iginisonu | ≤0.50% |
| Awọn Idẹ ti o jọmọ | (nipasẹ HPLC) |
| Aimọ Kanṣoṣo | ≤0.50% |
| Lapapọ Awọn Aimọ | ≤1.00% |
| Awọn irin Heavy | ≤20ppm |
| Ayẹwo | ≥99.0% |
| Awọn ohun elo ti o ku | Pade Specification |
| Igbesi aye selifu | 24 osu |
| Igbeyewo Standard | Standard Enterprise |
Apo:Igo, apo apamọwọ Aluminiomu, 25kg / Paali Drum, tabi gẹgẹbi ibeere alabara.
Ipò Ìpamọ́:Jeki apo eiyan naa ni wiwọ ni pipade ati tọju ni itura, gbẹ (2 ~ 8℃) ati ile-itaja ti o ni afẹfẹ daradara kuro ninu awọn nkan ti ko ni ibamu.Dabobo lati ina ati ọrinrin.
Gbigbe:Firanṣẹ si agbaye nipasẹ afẹfẹ, nipasẹ FedEx / DHL Express.Pese ifijiṣẹ yarayara ati igbẹkẹle.
Apejuwe Aabo 24/25 - Yago fun olubasọrọ pẹlu awọ ara ati oju.
UN ID UN 3077 9 / PGIII
WGK Germany 3
HS koodu 2933990099
Ewu Class IRRITANT
Crizotinib (CAS 877399-52-5), (Crizotinib, Xalkori R), jẹ agbara ati yiyan ATP ifigagbaga kekere moleku inhibitor ti ALK ati c-Met.Ni Oṣu Kẹjọ ọdun 2011, Amẹrika FDA fọwọsi Crizotinib fun itọju ti anaplastic lymphoma kinase (ALK) tunto akàn ẹdọfóró ti kii-kekere-kekere (NSCLC).Crizotinib jẹ oludaniloju ifigagbaga ATP meji ti tyrosine kinases c-MET (Mesenchymal-Epithelial Transition Factor) kinase (cellular IC50 = 8 nM) ati ALK (cellular IC50 = 20 nM), mejeeji ti awọn ibi-afẹde pataki fun chemotherapy akàn.Nigbati a ṣe idanwo crizotinib fun yiyan yiyan dipo kinases miiran o rii pe o ni henensiamu IC50's laarin 100-fold multiples ti c-MET fun 13 ti 120 kinases idanwo.Ninu awọn igbelewọn cellular, a rii crizotinib lati ṣe idiwọ RON (recepteur d’origine nantais) kinase pẹlu window yiyan-agbo 10 lori c-MET.
Crizotinib (PF-02341066) Crizotinib jẹ c-Met ti o lagbara ati inhibitor ALK, awọn iye IC50 ninu ayẹwo sẹẹli jẹ 11 nM ati 24 nM, lẹsẹsẹ.O tun jẹ inhibitor ti o lagbara ti ROS1 pẹlu iye Ki ti o kere ju 0.025 nM.Crizotinib le fa autophagy ni ọpọlọpọ awọn laini sẹẹli akàn ẹdọfóró nipasẹ didi ọna STAT3.
Crizotinib jẹ oludaniloju meji ti o lagbara ati yiyan ti mesenchymal-epithelial transition factor (c-MET) kinase ati anaplastic lymphoma kinase (ALK).Crizotinib jẹ aṣoju antitumor ti o pọju.Ni Oṣu Kẹjọ ọdun 2011, Amẹrika FDA fọwọsi crizotinib fun itọju ti anaplastic lymphoma kinase (ALK) ṣe atunṣe akàn ẹdọfóró ti kii-kekere-kekere (NSCLC).
Crizotinib (Xalkori (R), Pfizer), ti a fọwọsi ni ọdun 2011, jẹ oludena akọkọ ti a fọwọsi ti o fojusi anaplastic lymphoma kinase (ALK).ROS protooncogene 1-encoded kinase (ROS1) ti kilasi olugba insulin tyrosine kinase ati MET proto-oncogene-encoded kinase ti hepatocyte idagbasoke ifosiwewe receptor (HGFR) kilasi jẹ awọn kinases miiran ti a fojusi nipasẹ crizotinib. Nigbati a fọwọsi ni 2011, crizotinib ni akọkọ akọkọ. oogun pataki ti o fojusi awọn alaisan NSCLC.Sibẹsibẹ, resistance si crizotinib nigbagbogbo ni a ṣe akiyesi ni isunmọ awọn oṣu 8 lẹhin ohun elo akọkọ ati diẹ sii ju idaji awọn alaisan ti o ni itọju crizotinib ni iriri awọn ipa ẹgbẹ nipa ikun.Ni ọdun 2016, Crizotinib tun fọwọsi fun ROS1-rere NSCLC nipasẹ FDA.
Crizotinib (Xalkori) jẹ inhibitor tyrosine kinase olugba ti ẹnu ti a tọka si fun itọju awọn alaisan ti o ni ilọsiwaju tabi akàn ẹdọfóró ti kii-kekere sẹẹli (NSCLC).Awọn ipa ẹgbẹ ti o wọpọ pẹlu lilo Xalkori pẹlu ikolu ti atẹgun oke, ríru, ìgbagbogbo, irora inu, ifẹkufẹ dinku, insomnia, dizziness, rilara rirẹ, gbuuru, àìrígbẹyà, sisu tabi nyún, awọn aami aisan otutu (imu imu, sneezing, ọfun ọfun), numbness tabi tingling, tabi wiwu ni ọwọ tabi ẹsẹ rẹ.
